Investment Thesis
Ensysce Biosciences is a severely distressed pharmaceutical company with minimal revenue ($3.2M), massive operating losses (-$7.5M), and a -232.6% net margin indicating the business is burning cash at an unsustainable rate. With negative free cash flow of -$6.4M and only $1.7M in cash reserves against $2.3M in liabilities, the company faces imminent liquidity constraints and potential insolvency without significant capital infusion or operational turnaround.
Strengths
- Positive current ratio of 1.27x provides short-term liquidity cushion
- No long-term debt reduces leverage risk and balance sheet complexity
- Cash position of $1.7M provides runway for near-term operations
Risks
- Revenue of $3.2M is insufficient to cover operating expenses of $10.7M, indicating fundamental business model failure
- Negative free cash flow of -$6.4M will deplete $1.7M cash reserve in approximately 3 months at current burn rate
- Operating margin of -234.2% and net margin of -232.6% demonstrate the company is not close to profitability
- Zero insider purchases in last 90 days suggests lack of management confidence in the business
- ROE of -615.6% and ROA of -233.0% indicate severe shareholder value destruction
Key Metrics to Watch
- Monthly cash burn rate and months of cash runway remaining
- Revenue growth trajectory and path to profitability
- Insider buying activity as indicator of management confidence
Financial Metrics
Revenue
3.2M
Net Income
-7.4M
EPS (Diluted)
$-3.42
Free Cash Flow
-6.4M
Total Assets
3.2M
Cash
1.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-234.2%
Net Margin
-232.6%
ROE
-615.6%
ROA
-233.0%
FCF Margin
-201.1%
Balance Sheet & Liquidity
Current Ratio
1.27x
Quick Ratio
1.27x
Debt/Equity
0.00x
Debt/Assets
72.5%
Interest Coverage
-1,811.35x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T08:58:10.456947 |
Data as of: 2025-09-30 |
Powered by Claude AI